Brain Van Tine (Washington University in St Louis) joins us to discuss the results of the phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy (NCT02300545).
Questions
1. What are the limitations of standard first-line chemotherapy in the treatment of soft tissue sarcomas? (0:05)
2. What is the rationale for the use of pazopanib as first-line therapy in patients with non-resectable or metastatic soft tissue sarcomas? (0:45)
3. Could you tell us a little about the phase II study of pazopanib and its efficacy and safety findings? (1:35)
4. Which patients are most likely to benefit from this treatment approach? (2:37)
5. How common is pazopanib resistance and how might this be overcome? (3:16)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
